All Insights Report The Potential Of Real-World Evidence To Complement Basket Trials For Tissue-Agnostic Drugs Targeting Neurotrophic Tropomyosin-Related Kinase Gene Fusions

    The Potential Of Real-World Evidence To Complement Basket Trials For Tissue-Agnostic Drugs Targeting Neurotrophic Tropomyosin-Related Kinase Gene Fusions

    Real-World Evidence

    The Potential Of Real-World Evidence To Complement Basket Trials For Tissue-Agnostic Drugs Targeting Neurotrophic Tropomyosin-Related Kinase Gene Fusions

    Real-World Evidence to address limitation of Basket Trials for tissue-agnostic drugs targeting neurotrophic tropomyosin-related kinase gene fusions.

    The Potential Of Real-World Evidence To Complement Basket Trials For Tissue-Agnostic Drugs Targeting Neurotrophic Tropomyosin-Related Kinase Gene Fusions

    A basket trial is a study design in which study drug is tested simultaneously on patients with the same genetic mutation or biomarkers, regardless of the specificity of the cancer type. The goal is to identify whether the intervention drug is effective in treating the targeted genetic mutation or biomarker, rather than a specific type of cancer. This study aims to identify how alternative studies (including pooled analyses, real world studies, etc.) have been used to address the limitations of basket trials for rare patient populations treated with tissue-agnostic drugs.

    Contact us at connect@axtria.com with any questions.

    Complete the brief form to download the white paper

    Recommended insights

    RWE to Complement Basket Trials for Tissue Report

    White Paper

    The Evolution and Future of Integrated Evidence Planning

    RWE to Complement Basket Trials for Tissue Report

    Case Study

    Driving $25 Million Impact with a Data Science and Analytics Center of Excellence

    RWE to Complement Basket Trials for Tissue Report

    Industry Primer

    Real-World Evidence